Availability
0
Your Basket is Empty
AD15377

Doxorubicin HCl

Inhibitor of topoisomerase II with anti-neoplastic activity. The compound interferes with the topoisomerase II-mediated repair of DNA causing accumulation of mutations. Doxorubicin also leads to the generation of reactive oxygen species (ROS), which further damage DNA as well as proteins and membranes. However, the compound presents with a risk of developing cardiomyopathy as well as drug resistance.

Technical Data

CAS No: 25316-40-9
Synonyms: Adriamycin; (8S-cis)10-[(3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11- trihydroxy-8-(hydroacetyl)-1-methoxy-5,12- naphthacenedione; 14-Hydroxydaunomycin, HCl
Product Code: AD15377
MDL No: MFCD28988663
Chemical Formula: C27H29NO11·HCl
Molecular Weight: 579.98

References


  • Thorn et al (2011). Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and Genomics 21(7): 440–446.
  • Mizutani et al (2005). Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sciences 76(13):1439-1453.
  • Laginha et al (2005). Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clinical Cancer Research 11(19):6944-6949.
  • Weiss (1992). The anthracyclines: will we ever find a better doxorubicin? Seminars in Oncology 19(6):670-86.
  • Hutchinson and Colombo (1999). Genetic engineering of doxorubicin production in Streptomyces peucetius: a review. Journal of Industrial Microbiology and Biotechnology 23(1):647-52.

Solubility

Stability

Further Information


Datasheets

Specification: View
MSDS: View

CAS No:
25316-40-9
Synonyms:
Adriamycin
(8S-cis)10-[(3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11- trihydroxy-8-(hydroacetyl)-1-methoxy-5,12- naphthacenedione
14-Hydroxydaunomycin, HCl
MDL No:
MFCD28988663
Chemical Formula:
Molecular Weight:
579.98
Product Structure
References:
1. Thorn et al (2011). Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and Genomics 21(7): 440–446.
2. Mizutani et al (2005). Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sciences 76(13):1439-1453.
3. Laginha et al (2005). Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clinical Cancer Research 11(19):6944-6949.
4. Weiss (1992). The anthracyclines: will we ever find a better doxorubicin? Seminars in Oncology 19(6):670-86.
5. Hutchinson and Colombo (1999). Genetic engineering of doxorubicin production in Streptomyces peucetius: a review. Journal of Industrial Microbiology and Biotechnology 23(1):647-52.
Click for Specification
Click for MSDS

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...